Michael Davidson

American College of Cardiology Foundation provides cardiovascular education services. Its services include cardiac surgery, chronic angine, diabetes, geriatric cardiology and heart failure and cardiomyopathies. The company was founded by Franz Groedel, Robert P. Glover and Bruno Kisc in 1949 and is headquartered in Washington, DC.

Cerenis Therapeutics, Inc. discovers, develops and commercializes drugs for the treatment of cardiovascular and metabolic diseases. It focuses on discovery, development, and commercialization of HDL therapies. Cerenis Therapeutics is located in Ann Arbor, MI.

Abcentra, Inc. is an American clinical-stage biopharmaceutical company that specializes in developing novel antibody therapies for inflammatory diseases, with a particular focus on cardiovascular disease. The private company's patented technology allows for the targeting of oxidized lipoproteins and associated inflammatory responses. Abcentra's pipeline focuses on patient populations with high-risk of cardiometabolic complications that are exacerbated by chronic inflammation, including patients with inflammatory diseases and patients with residual inflammation. The company's lead compound, orticumab, is a novel monoclonal antibody that blocks inflammation from oxidized low-density lipoprotein and is slated to begin a phase 2 study later this year. Kevin B. Bacon has been the CEO of the company since 2020.

Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA.

Inositec AG develops small molecules as alternatives to antibiotics. It also develops a non-antibiotic small molecule that neutralizes the toxins secreted by clostridium toxins. The company was founded by Mattias Ivarsson, Bastien Castagner and Jean-Christophe Leroux in December 2015 and is headquartered in Zurich, Switzerland.

Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The private company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million.

Jocasta Neuroscience, Inc. provides biological products development services. The company is based in New Castle, DE.

NanoPhoria Srl is an Italian company that operates as a non-viral drug delivery platform. The company is based in Milan, Italy. The company was founded by Daniele Catalucci, Michele Iafisco, Alessio Alogna, Claudio de Luca. Claudio de Luca has been the CEO since incorporation.

Trofi Nutritionals, Inc. is a private company located in the US that is focused on advancing personal health management through next-generation nutritional wellness solutions. The American company works with partners to translate functional compound discoveries into nutritional solutions.

SonoThera, Inc. is a biotechnology company founded by Michael H. Davidson, Kenneth P. Greenberg, and Steve Feinstein. The company is based in South San Francisco, CA. The company is dedicated to treating the root cause of human disease through genetic therapy. SonoThera is developing an ultrasound-guided, nonviral gene therapy platform and treatments designed to provide patients with the next generation of safe and effective genetic medicines. The platform utilizes sonoporation, a microbubble-mediated biophysical process to non-invasively deliver genetic payloads selectively targeting a wide range of organs within the body. Kenneth P. Greenberg has been the CEO since incorporation.

The National Lipid Association aims to improve the practice of lipid management in clinical medicine. The non-profit company is based in Jacksonville, FL and has subsidiaries in the United States. The organization's mission is to enhance lipid management in clinical medicine, and its goals are consistent with this mission statement.

NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands.